VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on the company’s proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform. This represents an early but significant step in advancing the program toward clinical development.
The BiTAC-TCE platform is designed to selectively target cancer cells expressing both intended targets while sparing cells expressing only one target. Preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 demonstrated that the lead candidate exhibited a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index. This selectivity could reduce on-target, off-tumor toxicity, a common challenge in cancer immunotherapy, and potentially expand the therapeutic window for patients.
For business and technology leaders, this news matters because it underscores the progress in precision oncology—a field where dual-targeting and conditionally active biologics could redefine treatment paradigms. The regulatory alignment with a major European agency suggests that the platform’s scientific rationale is sound, de-risking future clinical development. If successful, BiTAC-TCE therapies could offer more effective and safer options for patients, potentially capturing significant market share in the bispecific antibody space, which is projected to grow substantially.
VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The BiTAC(R) trademark is registered to VERAXA Biotech GmbH.
The company also highlighted that the Paul-Ehrlich-Institute’s feedback validates the non-clinical development plan, which is crucial for designing clinical trials that meet regulatory requirements. This could accelerate the timeline to first-in-human studies, a key milestone for investors and partners. The full press release is available at https://ibn.fm/jpXam.
Forward-looking statements in the announcement remind stakeholders that actual results may differ materially due to risks and uncertainties, including those detailed in the company’s SEC filings. For the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
